A. Karim Kader, MD, PhD, argues that although PSA-based prostate cancer screening is flawed, urologists should adhere to the National Comprehensive Cancer Network (NCCN) Prostate Cancer Screening and Early Detection Guidelines. He outlines how, in order to avoid overdiagnosis and other issues, urologists can be more judicious as to which patients are offered screening, biopsy, and treatment, while not abandoning the use of PSA as a marker for prostate cancer altogether.
Ещё видео!